aTyr Pharma (LIFE) Tops Q2 EPS by 4c

aTyr Pharma (NASDAQ: LIFE) reported Q2 EPS of ($0.69), $0.04 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $189 thousand versus the consensus estimate of $400 thousand.

“While the advent of the global COVID-19 pandemic impacted our Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis, hindering patient enrollment during the second quarter, I am pleased that the majority of our sites are now continuing enrollment. Due to the strong scientific rationale of ATYR1923’s mechanism of action and its overlap with COVID-19 disease pathology, including inflammatory lung injury, during the second quarter we also initiated a Phase 2 trial of ATYR1923 in COVID-19 patients with severe respiratory complications,” said Dr. Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr.

“Additionally, we continue to drive value and build momentum with our pipeline. The preclinical data resulting from our Neuropilin-2 (NRP2) antibody program in oncology demonstrates tumor inhibitory effects and we expect to declare an Investigational New Drug (IND) candidate later this year. We also expect to complete the first phase of our tRNA synthetase research collaboration with CSL Behring early in the fourth quarter.”

For earnings history and earnings-related data on aTyr Pharma (LIFE) click here.

You May Also Be Interested In

• Visa (V) stock rises as Q2 earnings, revenue come ahead of estimates
• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• West Fraser Timber Co. Ltd. (WFG) Tops Q1 EPS by 17c